Clinical trials: Tremelimumab
Uveal Melanoma
Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma
This is a Phase 2, multi-center, open-label study in patients with surgically incurable stage III or IV uveal melanoma who have not received prior immunotherapy.
- Trial name
- NCT01034787
- Testing
- CP-675,206
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AHS Cancer Control Alberta
HCC - Hepatocellular Carcinoma, Tremelimumab
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%.
- Conditions
- HCC - Hepatocellular Carcinoma, Tremelimumab, Durvalumab, Radiotherapy
- Trial name
- Photon-STRIDE (NCT06999707)
- Testing
- Photon radiotherapy, Tremelimumab, Durvalumab
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of…
- Trial name
- HIMALAYA (NCT03298451)
- Testing
- Durvalumab, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2)
- Where
- 160 sites in United States, Brazil and 15 more
- Volunteers
- 1,324 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases
This study is evaluating the combination of Y-90 radioembolization followed by SBRT with the immunotherapy drugs, durvalumab and tremelimumab, to improve disease control of liver metastases for patients with microsatellite stable…
- Trial name
- NCT03802747
- Testing
- Durvalumab, Durvalumab and Tremelimumab, Y-90 Selective Internal Radiation Therapy (SIRT)
- Sponsor
- University of Colorado, Denver
Hepatocellular Carcinoma
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
- Trial name
- TREMENDOUS (NCT05557838)
- Testing
- Durvalumab, Tremelimumab
- Where
- 29 sites in China
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Pancreatic Adenocarcinoma
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
- Trial name
- NCT02879318
- Testing
- Gemcitabine, Nab-paclitaxel, Durvalumab
- Where
- 27 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Bladder Cancer, High-Risk Cancer
Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer
We will conduct a Phase I trial testing whether local cystoscopic injection of tremelimumab into the bladder wall in combination with systemic administration of durvalumab in localized bladder cancer will stimulate an effective…
- Conditions
- Bladder Cancer, High-Risk Cancer, Tremelimumab, Durvalumab
- Trial name
- Rideau (NCT05120622)
- Testing
- Tremelimumab
- Where
- Canada
- Sponsor
- University of British Columbia
Carcinoma, Non-Small Cell Lung
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible.
- Trial name
- NCT04499053
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Georgetown University
Cholangiocarcinoma
Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)
This pilot trial will be used to assess the activity, safety and feasibility of doublet immunotherapy and platinum-based chemotherapy in resectable intrahepatic cholangiocarcinoma with high risk features.
- Trial name
- ICC (NCT04989218)
- Testing
- Novel combination of chemotherapy and immunotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Breast Cancer
Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer
The aim of this study is to evaluate the safety and efficacy of anti PD-L1 antibody + anti CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor positive HER2-negative recurrent or metastatic…
- Trial name
- NCT03430466
- Testing
- Durvalmab&Tremelimumab&Fulvestrant
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Kyoto Breast Cancer Research Network
Mesothelioma, Malignant
......SMARTEST Trial......
The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B)…
- Trial name
- NCT05380713
- Testing
- Cyclophosphamide, Tremelimumab, Durvalumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
This is a randomized, open, comparative, multi-centre study which will recruit up to 66 patients. The objective is mainly to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with…
- Trial name
- INeOV (NCT03249142)
- Testing
- ARM A Durvalumab/chemotherapy association, ARM B Durvalumab/Tremelimumab/chemotherapy association
- Where
- 11 sites in France
- Volunteers
- 69 people
- Sponsor
- ARCAGY/ GINECO GROUP
Biliary Tract Neoplasms
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
<Research Hypothesis> The dynamics of immune systems by cytotoxic chemotherapy and its changes by combination with immuno-oncology agents will be uncovered.
- Trial name
- NCT03046862
- Testing
- Durvalumab, Tremelimumab, Gemcitabine
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Seoul National University Hospital
Stage III NSCLC
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
- Trial name
- Induction (NCT04287894)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Small Cell Lung Carcinoma Extensive Disease
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab…
- Trial name
- CASPIAN (NCT03043872)
- Testing
- Durvalumab, Tremelimumab, Carboplatin
- Where
- 207 sites in United States, Argentina and 21 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous…
- Trial name
- TRITON (NCT06008093)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- 47 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX.
- Trial name
- NCT02962063
- Testing
- durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Immunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas.
- Trial name
- NCT03283605
- Testing
- SBRT, Durvalumab, Tremelimumab
- Where
- 3 sites in Canada
- Volunteers
- 33 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Urothelial Cancer
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in…
- Trial name
- NCT02516241
- Testing
- MEDI4736 (Durvalumab), Tremelimumab, Cisplatin
- Where
- 222 sites in United States, Australia and 22 more
- Volunteers
- 1,126 people
- Sponsor
- AstraZeneca
Squamous Cell Carcinoma of the Head and Neck
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC
Phase II trial evaluating to assess the feasibility and efficacy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC of Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in…
- Trial name
- DURTRE-RAD (NCT03624231)
- Testing
- Durvalumab, Tremelimumab, Radiotherapy
- Where
- 3 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Ulrich Keilholz